Medtech deals surge into Q4
Would you invest in a startup developing a cardiovascular surgical device? If yes, you’re not alone: It’s been the most active category for medtech investment in 2023 year to date, with $487.7 million in VC funding in Q3 alone. Cancer diagnostics and surgical robotics have also been locking up major dollars, according to our Q3 2023 Medtech Report.
Leading the pack are names such as Neuralink and Beta Bionics, both of which closed nine-figure deals in late Q3, setting the stage for a strong finish for the year.
Table of contents
| Vertical update | 3 |
| Q3 2023 timeline | 5 |
| Medtech landscape | 6 |
| Medtech VC and PE ecosystem market map | 7 |
| VC and PE activity | 9 |
| Emerging opportunities | 13 |
| Voice-based diagnostics | 14 |
| Minimal residual disease | 16 |
| Select company highlights | 18 |
| Beta Bionics | 19 |
| Noah Medical | 21 |
| Appendix | 23 |